Caroline Palomeque
Stock Analyst at Maxim Group
(1.85)
# 3,621
Out of 5,182 analysts
10
Total ratings
55.56%
Success rate
1.06%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Caroline Palomeque
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DARE Daré Bioscience | Upgrades: Buy | $8 | $2.24 | +257.14% | 3 | Sep 4, 2025 | |
| HRMY Harmony Biosciences Holdings | Initiates: Buy | $59 | $31.05 | +90.02% | 1 | Sep 7, 2023 | |
| KRYS Krystal Biotech | Initiates: Buy | $154 | $272.75 | -43.54% | 1 | Sep 7, 2023 | |
| HALO Halozyme Therapeutics | Reinstates: Buy | $58 | $64.49 | -10.06% | 1 | Mar 27, 2023 | |
| ASND Ascendis Pharma | Assumes: Buy | $166 | $226.66 | -26.76% | 1 | Aug 30, 2022 | |
| DNLI Denali Therapeutics | Initiates: Buy | $39 | $19.94 | +95.59% | 1 | Jun 23, 2022 | |
| RGNX REGENXBIO | Initiates: Buy | $61 | $8.62 | +607.66% | 1 | Jun 23, 2022 | |
| AVXL Anavex Life Sciences | Initiates: Buy | $40 | $3.29 | +1,115.81% | 1 | Jun 23, 2022 |
Daré Bioscience
Sep 4, 2025
Upgrades: Buy
Price Target: $8
Current: $2.24
Upside: +257.14%
Harmony Biosciences Holdings
Sep 7, 2023
Initiates: Buy
Price Target: $59
Current: $31.05
Upside: +90.02%
Krystal Biotech
Sep 7, 2023
Initiates: Buy
Price Target: $154
Current: $272.75
Upside: -43.54%
Halozyme Therapeutics
Mar 27, 2023
Reinstates: Buy
Price Target: $58
Current: $64.49
Upside: -10.06%
Ascendis Pharma
Aug 30, 2022
Assumes: Buy
Price Target: $166
Current: $226.66
Upside: -26.76%
Denali Therapeutics
Jun 23, 2022
Initiates: Buy
Price Target: $39
Current: $19.94
Upside: +95.59%
REGENXBIO
Jun 23, 2022
Initiates: Buy
Price Target: $61
Current: $8.62
Upside: +607.66%
Anavex Life Sciences
Jun 23, 2022
Initiates: Buy
Price Target: $40
Current: $3.29
Upside: +1,115.81%